Potential Aprea Therapeutics, Inc. (NASDAQ:APRE) shareholders may wish to note that the Independent Director, Marc Duey, recently bought US$132k worth of stock, paying US$4.39 for each share. That's a very decent purchase to our minds and it grew their holding by a solid 14%.

View our latest analysis for Aprea Therapeutics

Aprea Therapeutics Insider Transactions Over The Last Year

In fact, the recent purchase by Marc Duey was the biggest purchase of Aprea Therapeutics shares made by an insider individual in the last twelve months, according to our records. That means that an insider was happy to buy shares at above the current price of US$4.18. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. In our view, the price an insider pays for shares is very important. As a general rule, we feel more positive about a stock if insiders have bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price.

Aprea Therapeutics insiders may have bought shares in the last year, but they didn't sell any. Their average price was about US$4.86. This is nice to see since it implies that insiders might see value around current prices. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them).

Insider Ownership Of Aprea Therapeutics

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. From our data, it seems that Aprea Therapeutics insiders own 12% of the company, worth about US$2.8m. Overall, this level of ownership isn't that impressive, but it's certainly better than nothing!

So What Do The Aprea Therapeutics Insider Transactions Indicate?

The recent insider purchases are heartening. And the longer term insider transactions also give us confidence. But we don't feel the same about the fact the company is making losses. We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that Aprea Therapeutics insiders are expecting a bright future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. To help with this, we've discovered 6 warning signs (1 can't be ignored!) that you ought to be aware of before buying any shares in Aprea Therapeutics.